After four lessons it is easy to start seeing amblyopia everywhere acuity is "not right". This is exactly the moment when the module has to put up a guard rail.
Plasticity does not cancel organic disease. If there is a relative afferent pupillary defect (RAPD) — an asymmetry of the pupillary response to the swinging flashlight: when the light is moved to the worse-seeing eye both pupils paradoxically dilate, because the afferent signal from that eye is weaker — or disc pallor, a macular scar, untreated glaucoma, the structure is explained first. Typical amblyopia does not produce an RAPD of a degree that would explain acuity of the order of 20/200: that is a sign of optic nerve asymmetry or massive retinal loss, not of a "lazy eye". An amblyopic component can coexist, and the PPP acknowledges this. But "the critical period" does not treat optic atrophy. At the checkpoint and in the exam there will be a case where the temptation to call it amblyopia is stronger than the grounds for doing so.
Plasticity is not the same as adherence. The most plastic age coincides with the age at which the patch is removed after five minutes. PEDIG has shown repeatedly that prescribed hours and hours actually worn are different quantities. Atropine in ATS1 had slightly higher acceptability on the parental questionnaire. This does not make the drop "physiologically stronger" — it makes the regimen feasible.
Plasticity is not evidence for a commercial method. Games, flicker glasses, "neurostimulation", biofeedback courses, the promise to "reopen the critical period" in a schoolchild in two weeks live in the same linguistic zone as the real Hubel–Wiesel neurobiology. Module 4 will sort this into baskets. Here the rule is enough: a mechanism in an animal or in a small laboratory series does not carry over into a prescription until it has been tested in an RCT in the right age and diagnostic group.
What Module 1 does not cover.
- The classification of forms and the refractive thresholds at which a factor is considered amblyogenic — Module 2.
- How exactly to measure acuity so as not to mistake crowding for "good vision" — Module 3.
- Which occlusion and atropine regimens have withstood head-to-head comparison — Module 4.
- Surgery for cataract, ptosis and strabismus — adjacent disciplines; here only the urgency of deprivation and the reminder that aligning the eyes does not replace treating amblyopia.
- Adults as a target group for PPP protocols.
A teaching case at the boundary. A 16-year-old, amblyopia of 20/100, wore glasses irregularly, no patching. The family asks for "a last chance". The PPP says: offer an attempt, especially if not previously treated. ATS3 says: in the 13–17 stratum, adding occlusion and atropine to optics showed no advantage in the proportion of responders over optics alone. An honest plan: full optical correction, a realistic timeframe for assessing response, no promise of "like at age three" and no withdrawal of follow-up. That is the clinical use of age: not as a prohibition and not as a guarantee, but as a modifier of the expected effect.